 |
 |
 |
Ketorolac |
|
Zyprexa Fluoxetine Itraconazole Adapalene |
Dr. Daniels is the executive medical director, SCIREX, Austin, Texas. Dr. Hubbard is vice president, Allergy and Respiratory Diseases, Pfizer Global Research and Development, PGRD Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, Mich. 48105, e-mail "richard.c.hubbard pfizer ". Address reprint requests to Dr. Hubbard. The authors wish to acknowledge the subinvestigators who performed the surgical procedures in this study: Drs. Dean Jasper, Steven Perkins and Sinclair Short. They also wish to thank Alicia Bauman, R.N., B.S.N., the site manager and lead research coordinator for this study, who organized the efforts of the research staff. 1. Joris J. Efficacy of nonsteroidal antiinflammatory drugs in postoperative pain. Acta Anaesthesiol Belg 1996; 47 3 ; : 115-23. 2. Moote C. Efficacy of nonsteroidal anti-inflammatory drugs in the management of postoperative pain. Drugs 1992; 44 supplement 5 ; : 14-29. 3. Litvak KM, McEvoy GK. Ketorolac, an injectable nonnarcotic analgesic. Clin Pharm 1990; 9: 921-35. Mandema JW, Stanski DR. Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 1996; 60: 619-35. Nuutinen LS, Laitinen JO, Salomki TE. A risk-benefit appraisal of injectable NSAIDs in the management of postoperative pain. Drug Saf 1993; 9: 380-93. Hoogewijs J, Diltoer MW, Hubloue I, et al. A prospective, open, single blind, randomized study comparing four analgesics in the treatment of peripheral injury in the emergency department. Eur J Emerg Med 2000; 7 2 ; : 119-23. 7. Lewis S. Keto4olac in Europe. Lancet 1994; 343: 784. Choo V, Lewis S. Ketorllac doses reduced. Lancet 1993; 342: 109. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA 1999; 282: 1921-8. Geis GS. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? J Rheumatol 1999; 26 supplement 56 ; : 31-7. 11. Malmstrom K, Daniels S, Kotey P, Seidenberg BC, Desjardins PJ. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and activecomparator-controlled clinical trial. Clin Ther 1999; 21: 1653-63. Morrison BW, Christensen S, Yuan W, Brown J, Amloni S, Seidenberg B. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Ther 1999; 21: 943-53. Bensen WG, Zhao SZ, Burke TA, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 2000; 27: 1876-83. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal adverse effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929-33. Talley JJ, Brown DL, Carter JS, et al. valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 2000; 43: 775-7. Bikhazi GB, Baiwa ZH. A clinical trial demonstrating the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecology surgery with laparotomy. J Obstet Gynecol 2004; 191: 1183-91. Barton SF, Langeland FF, Snabes MC, et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology 2002; 97: 306-14. Rasmussen GL, Steckner K, Hogue C, Torri S, Hubbard RC. Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. J Orthop 2002; 31: 336-43. Daniels SE, Grossman EH, Kuss ME, Talwalker S, Hubbard RC. A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model. Clin Ther 2001; 23: 1018-31. Mehlisch DR, Desjardins PJ, Daniels S, Hubbard RC. Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. J Oral Maxillofac Surg 2003; 61: 1030-7. Desjardins PJ, Shu VS, Recker DP, Verburg KM, Woolf CJ. A single preoperative oral dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain. Anesthesiology 2002; 97: 565-73. Fricke JR Jr, Angelocci D, Fox K, McHugh D, Bynum L, Lee JP.
ASSOCIATION OF FACULTIES OF PHARMACY OF CANADA ASSOCIATION DES FACULTS DE PHARMACIE DU CANADA MINUTES 58th ANNUAL GENERAL MEETING SATURDAY, JUNE 16, OTTAWA, ON 1.0 Opening Remarks- President David Fielding welcomed all those in attendance to the 58th Annual Meeting of AFPC. A special welcome was extended to CAPSI president and vice president Kevin Duplisea and Trevor Kennedy; Jim Mann, Executive Director of CSHP President Fielding introduced Executive and Council members as well as AFPC Communications editor, Rebecca Law. 2.0 3.0 4.0 Acceptance of 2000 Annual General Meeting Minutes - The motion to accept the minutes of the 2000 AGM was approved Frank Abbott and Don Perrier ; . Conference Committee Announcements - There was no announcements necessary. Greetings 4.1 Dr. Richard Penna, Executive Vice President, American Association of Colleges of Pharmacy - Dr. Penna brought greetings from AACP and extended an invitation for AFPC members to attend the AACP conference in Toronto meeting, July 7 - 11th, 2001. In response to the growing demand for pharmacy graduates, five new colleges of pharmacy are in the process of initiating programs and another five are seriously considering the establishment of pharmacy programs. AACP is currently pursuing funding sources from government to assist with the human resource issues. Two new non-traditional providers have developed programs and pharmacy education must rethink its role - are we in the business of pharmaceutical education or just colleges of pharmacy? 5.0 6.0 Memorial to Deceased Members - President Fielding called for a minute silence in memory of Dr. Mervyn Huston President s Address - David Fielding President Elect Rmillard requested the President to present his report. He indicated that it was a very successful year for AFPC and identified seven areas of accomplishment: our joint annual conference with CCCP together with the CSPS conference being held at the same time in the same hotel; the publication of The History of the Association of Faculties of Pharmacy of Canada: The First Fifty Years 1944 - 1994; the continuing process of assisting faculties to develop their curricula and to strengthen their instructional and evaluation tools; a strong external relations program; the success of the new membership structure and the updated process for both internal and external communications with special note of excellent work being done by AFPC Communications Editor, Rebecca Law the excellent Awards Program 80, for instance, ketorolac injection.
Case 1 A 36-year-old previously healthy man presented to the emergency department complaining of back pain and heartburn that began gradually while installing a carpet. The pain was increasing to the point where he had difficulty moving his arms and difficulty sleeping. In the emergency department, the discomfort was relieved with administration of ketorolac, 60 mg, and an antacid, and he was sent home with the diagnosis of "musculoskeletal pain and dyspepsia." The patient returned to the emergency department 1 week later noting return of his back pain and mild general fatigue. His temperature was elevated to 38.1C and the WBC count was elevated at 19, 600 L. Because of the patient's elevated temperature and leukocytosis, blood cultures were obtained. The patient was released from the emergency department at his request, after obtaining relief of the pain with intramuscular injection of ketorolac, 30 mg. The blood cultures were positive for group A -hemolytic Streptococcus S pyogenes ; and the patient was called back to the hospital for parenteral antibiotic therapy. Physical examination was notable for poor dentition, a three-component pericardial friction rub along the lower left sternal border, and a 1 6 systolic!
Ii - ketorolac ophthalmic ; ketorolac ophthalmic ; some commonly used brand names are: in the acular in canada acular category anti-inflammatory, nonsteroidal, ophthalmic antipruritic, ophthalmic description ophthalmic ketorolac kee-toe-role-ak ; is an anti-inflammatory medicine. General information: if you have any questions about ketorolac , please talk with your doctor, pharmacist, or other health care provider. Ketorolac Placebo * Mean and standar d deviation. 68.6 64.2 and ketotifen. Spriodela, multiflower knotweed root, Xanthium, Chinese angelica root, scorpion, safflower and chuanxiong rhizome. Finally, from Cuba comes `.the only medicine in the world that cures [vitiligo] in more than 80% of cases'. Melagenina -- `the substance that generates melanin' -- is an extract of human placenta. It was discovered by Dr Carlos Miyares Cao in 1968, and was apparently shown to have a cure rate of 84 per cent `without secondary effects nor backward movements'. The original three-times daily application plus infra-red irradiation has been replaced with a more convenient once daily application that does not require additional irradiation, which is reported to be more efficacious than the original. Experience has shown that this product will take several years to reduce the extent of vitiligo on the body. The diversity of treatments on offer and the exaggerated and unsubstantiated claims are symptoms of the paucity of rapidly effective proven treatments for vitiligo. Most alternative treatments are supported by anecdotal reports or poor quality studies. There is no doubt that many patients benefit from treatment and that more good research is needed to determine the relative merits of each approach. Figure 4 The correlation between the relative amounts of ketorolac and deuterium-labelled phospholipid DLP ; in the tape-strips of 1 h elastic vesicle application. The relative amount of ketorolac is expressed as the percentage of the total amount of drug applied on the skin surface 100 mg ; and the relative amount of DLP is expressed as the relative peak area of the CD symmetrical and asymmetrical stretching vibrations. There is a very good correlation between the ketorolac and the DLP up to approximately tape-strip 35. From tape-strip 35 onwards, there is no good correlation anymore. From this point onwards the relative amount of DLP increases, whereas the relative amount of ketorolac decreases. These results suggest that ketorolac was associated with the vesicle material in the upper and middle parts of the SC, but was released from the vesicle material in the lowest part of the SC and lamictal. Prior Introductions: None. Cross File: None. Information Source s ; : Maryland Department of the Environment, Department of State Police, Department of Health and Mental Hygiene, Department of Public Safety and Correctional Services, Anne Arundel County Police Department, Anne Arundel County Health Department, Baltimore County Police Department, U.S. Department of Justice U.S. Drug Enforcement Administration ; , Department of Legislative Services Fiscal Note History: ncs ljm First Reader - March 6, 2006. G gemfibrozil .9, 10 Genotropin .13 Geocillin.3 Geodon .7 Geref .13 Gleevec .14 glipizide .11 glipizide ER .11 glipizide tablet, sustained release osmotic push.11 Glucophage .11 Glucophage XR.11 Glucotrol .11 Glucotrol XL .11 glyburide .11 glyburide, micronized.11 glyburide metformin HCl .11 Glynase .11 Glyset .11 Grifulvin V Suspension .4 Grifulvin V Tablet.4 griseofulvin ultramicrosize .4 Gris-Peg .4 guanfacine HCl .9 Gynazole-1 .5 H Halcion .6 haloperidol .7 haloperidol lactate concentrate, oral.7 Hepsera.5 Humalog, Mix.11 Humalog .11 Humatrope.13 Humulin .11 hydralazine HCl hydrochlorothiazide .10 hydrochlorothiazide .10 hydroxyzine HCl .17 hydroxyzine pamoate .17 Hytrin .9 Hyzaar .9 I ibuprofen .15 imipramine HCl .6 Imitrex.5 Imitrex NS.5 Inderal.8 Inderal LA.8 Inderide LA .10 Indocin .15 indomethacin .15 indomethacin capsule, sustained action.15 Infergen .14 Innopran XL.8 Intal Inhaler .16 Intron A .13, 14 Iplex .14 ipratropium bromide solution, non-oral .16 isoetharine HCl solution, non-oral .15 itraconazole .4 K Keflex.3 Keftab .3 Kepivance.13, 14 Kerlone.8 ketoconazole .4 ketoprofen.15 ketoprofen capsule, 24 hr sustained release pellets.15 ketorolac.15 Kineret .14 Kytril TAB.5 L labetalol HCl .8 Lamisil Tablet.4 Lamisil.4 Lantus.11 Lescol .10 Lescol XL .10 Leukine.13 Levaquin .4 Levatol.8 Levlen .12 Levlite.12 and lamotrigine. Douglas B. Schwartz, MD, is associate professor of medicine at the Albany Medical College and an attending staff pulmonologist intensivist at the Stratton Veterans Affairs Medical Center in Albany, N.Y. We are grateful to the Zhejiang Xian Ju Pharmaceutical Corp. for providing the injectable TU preparation. We thank Drs. Xiao-wei Liang and Wen-hong Lu and Zheng-yan Ge for their excellent technical assistance in hormone assays and biochemistry measurements. We gratefully acknowledge the help of Mr. Jing Dong with performing the statistical analysis and Ms. Jie Cong with data collection and monitoring. We also gratefully acknowledge the Contraceptive Research and Development Program for providing the research grant and Professor Jean M. Kaufman for kindly providing the free T calculator. We also gratefully acknowledge Drs. Kirsten Vogelsong and Doug Colvard for reviewing and commenting on a previous version of this manuscript. Received July 28, 2003. Accepted February 3, 2004. Address all correspondence and requests for reprints to: Yi-Qun Gu, M.D., Associate Professor, Department of Male Clinic Research, National Research Institute for Family Planning, Beijing 100081, China. E-mail: ygu90 hotmail and levothyroxine.
Giarised articles from several leading journals, including the BMJ, the British Journal of Obstetrics and Gynaecology, Cancer, the Lancet, and the New England Journal of Medicine. In one case, sections of papers from the BMJ 1989; 298: 642-4 ; and the New England Journal of Medicine 1992; 327: 70-5 ; were combined to form a separate publication in Zentralblatt fr Gynkologie 1993; 115: 161-6 ; . Dr Wronski explains: "This case attracted my attention, and I began to investigate [Dr Jendryczko's] long list of publications. Using PublicMedline, nearly 30 articles were discovered where the text was taken nearly verbatim from different medical journals. The majority of his articles were published between 1984 and 1996 in Polish in the national journals, but some were submitted in English to less well known European journals like Zentralblatt fr Gynkologie." Dr Jendryczko is still working for the Polytechnic Institute of Czestochowa, while investigations are being completed. In a letter to Rzeczpospolita on 14 January he denied Dr Wronski's allegations and loxapine. Ketorolac vs vicodinPatients who experience gastrointestinal irritation may benefit from administration of the drug with food or by a progressive increase of the dose from an initial low level. Methanol 100 % ; was controlled to accommodate their retention times. Lower limit of detection was 20 ng mL, calibration curves were constructed at the concentration range of 0.02-50 g mL, and an excellent linearity was observed between the peak area ratios and drug concentrations over this range r 0.993 ; . Least-squared regression method was used to determine the regression coefficients and the equation for the best fitting line. The accuracy of the method was 90 % and coefficient of variation CV ; did not exceed 10 %. Data were compared for statistical significance by one way analysis of variance ANOVA ; . The statistical significance of means was compared by multiple range method of least significant difference. RESULTS Capacity factors K ; are represented in Table 1. K values were proportional to the side chain length. Esters except palmitoleate ; were highly stable toward chemical hydrolysis in the tested pH range Fig 2 ; . They were relatively unstable in liver and skin homogenates Fig 3 ; . Irrespective of the test media, highest esterase stability was observed for decenoate followed by dodecenoate and palmitoleate. In skin permeation study, unlike parent ketorolacc control ; , none of the esters were detected in the receptor solution from all skins. Ester accumulation in all skins was significantly higher compared parent ketorolac P 0.0033 ; Table1, Fig 4 ; , and it decreased with the increment in K values Fig 5 ; . In all skins, the highest accumulation was observed for decenoate P 0.05, compared to dodecenoate and palmitoleate ; . In normal and SC stripped skins, the accumulation of dodecenoate was significantly higher P 0.004 ; compared to palmitoleate. There was no significant difference in the accumulation of ketorolac P 0.32 ; , dodecenoate P 0.05 ; and palmitoleate P 0.05. 1. Bhopal R. What is the risk of coronary heart disease in South Asians? A review of UK research. J Public Health Med 2000; 22: 37585. Bhopal R. 2002 ; Epidemic of cardiovascular disease in South Asians. BMJ 2002; 324: 6256 and ketotifen. Q LYRICA q METHADONE DOLOPHINE ; q MS CONTIN q NAPROSYN ALLEVE q NEURONTIN q NORTRIPTYLINE PAMELOR ; q ORAMORPH q OXYCODONE PERCOCET, TYLOX ; q OXYCONTIN q PAXIL q PENTAZOCINE HCI TALWIN ; q PROPOXYPHENE DARVOCET ; q PROZAC q RITALIN q SERZONE. q SKELAXIN q SOMA q TEGRETOL q TOPAMAX q TORADOL KETOROLAC ; q TRAZADONE DESYREL ; q ULTRAM TRAMADOL ; q VALIUM q WELLBUTRIN q XANAX q ZANAFLEX q ZOLOFT WORK: Do you work? q NO q YES If yes, what do you do? If no, how long have you been out of work? If you do not work, how do you spend your day? Have you ever been in the military? INCOME: Do you have medical insurance? Are you on Disability? q NO q YES Type q NO q YES q NO q YES q NO q YES Are you able to do household chores? q NO q YES explain if no. Undergraduate medical students: Geriatric Medicine faculty is involved in teaching two modules in I.T.P. This is the fourth year that we are teaching the undergraduate students under the new curriculum. In the ICMB period we received half the class one half day per week for ten weeks and the other half of the class does the same for another ten weeks. Dr. John Kirk is responsible for this program and thus far the evaluations have been particularly positive. Medical residents: All medical residents as well as neurology residents have a one month rotation in Geriatric Medicine in their first year. Dr. Yves Bacher is now responsible for this program. Family medicine residents: All family medicine residents as well do one month of Geriatric Medicine. Health care for the Elderly Training Program: In the past eight years we have trained 14 fellows. Dr. Najmi Nazerali is the Director, and Dr. Sylvia Windholz is the Associate Director of this program. This year one fellow was admitted to the program and we will have three fellows in the upcoming academic year. Geriatric Medicine Specialty Training Program: Dr. Allan Huang is the Program Director. Dr. Shek Fung is completing his R6. Dr. Cara Tannenbaum is completing her R5. Dr. Wendy Chiu, as well as Dr. Gustavo Duque, a fellow from Columbia, have completed their R5. As indicated previously, Dr. Duque will begin his Ph.D. while Dr. Chiu will do a year of training in Clinical Epidemiology in Toronto. 2.2 Post-graduate Courses. Opioid administration is still the most common treatment of choice for acute postop pain, but undesirable side effects, such as respiratory depression, PONV and sedation, may offset the benefits. This has led to widespread use of nonsteroidal anti-inflammatory drugs NSAIDs ; in the ambulatory setting. For the treatment of acute postoperative pain, fentanyl provides superior analgesia within the first 15-minutes than ketorolac; while both groups are equally effectively in providing pain relief thereafter 16 ; . Ketoolac 30-60 mg 0.5-1mg kg ; has been shown to provide effective analgesia with less emetic symptoms than opioids 17 however, the potential for increased bleeding may limit its usefulness after some surgical procedures 18 ; . The cyclooxygenase COX-2 ; inhibitors, a new class of NSAIDs designed specifically to limit GI side effects and bleeding, do not have this drawback. Two such drugs- Celecoxib Celebrex ; and Rofecoxib Vioxx ; are currently available and have been approved for the treatment of osteoarthritis, acute pain and dysmenorrhea 19 ; . COX-2 selective NSAIDs may well represent advancement over nonselective NSAIDs with respect to GI complications and platelet aggregation. However, further studies to establish the time of onset, degree of analagesia, and the risk benefit ratios of these new NSAIDs are warranted before endorsement as a benchmark for acute postoperative pain control in the ambulatory setting. Oral opioid-nonopioid combinations are usually adequate to control mild to moderate postop pain. The use of local anesthetic wound infiltration, intra-articular analgesics, and specific nerve blocks are particularly useful in reducing post-operative analgesic requirements, and are strongly encouraged 20 ; . The optimal postoperative pain management is achieved by a multimodal or balanced approach 21 ; , where combinations of systemic opioids, regionl nerve blocks and adjuvants such as nonsteroidal anti-inflammatory drugs, reduce the incidence and severity of opioid-related side effects while preserving the desired benefit of effective pain relief. POSTOPERATIVE NAUSEA AND VOMITING Despite pharmacological and technological advancements, nausea and vomiting still remain common problems for postsurgical outpatients, seen in 20% -30% of patients after general anesthesia 22 ; , and reported by 35% of patients after discharge home 23 ; . Prophylactic measures are advised for the highly vulnerable patients - females, patients in the luteal and perimenstrual phases of the menses cycle, history of PONV, non-smokers and those with motion sickness 24 ; . Certain surgical procedures, namely laparoscopy, strabismus repair, orchiopexy and termination of pregnancy are proven precipitating factors. Droperidol, metoclopramide, and prochlorperazine are effective against PONV in the ambulatory setting; however, their effectiveness is often negated by the undesirable side effects, such as extrapyramidal reactions, marked sedation and drowsiness. Anti-serotonin drugs e.g., ondansetron, dolasetron ; , in contrast, provide effective PONV management without these undersirable side effects, and work by blocking central and peripheral receptors that modulate the vomiting reflex. Side effects, although infrequent, may include headache, dizziness and transient elevated liver enzymes. Antiemetic prophylaxis with droperidol 0.625-mg IV, droperidol 1.25-mg IV, ondansetron 4-mg IV or dolasetron 12.5-mg is similarly efficacious in adults compared to metoclopramide 10-mg IV 25-27 ; . Ondansetron, however, is more effective than droperidol in preventing vomiting in children 28 ; . While the timing of prophylactic ondansetron does not appear to affect the overall incidence of PONV, the need for rescue antiemetic to treat breakthrough PONV may be reduced when it is administered at the end of surgery 29 ; . In addition, dexamethasone prophylaxis 150 g kg, up to 8-mg ; appears to further decrease the risk of PONV, and provide an extended duration of action lasting up to 24-h postoperatively 30 ; . Practitioners have conflicting opinions regarding the utility of routine prophylaxis against PONV 31 ; . Watcha has provided an algorithm ranging from routine mulitmodal antiemetic prophylaxis for the high-risk patients to none for low-risk patients 10% risk of PONV ; , and also identified risk factors 22, 32 ; . Notwithstanding these differences, timely. West lafayette, in 4790 2 charles jordan professor school of pharmacy purdue university west lafayette, in 4790 * correspondence to patrick stahly, ssci, inc purdue research park 1291 cumberland ave! The new strategies of pharmacologic pain treatment are increasing rapidly due to the availability of new drugs modulating the no-activated cascade and soon may be available for clinical use, because ketorolac trom! For more detailed information about your Envision Rx Plus prescription drug coverage, please review your Envision Rx Plus EOC and other plan materials. If you have questions about Envision Rx Plus, please call Member Service at 866-2502005, 7 days a week 24 hours a day. TTY TDD users should call 866-763-9630. Or visit envisionrxplus . If you have general questions about Medicare prescription drug coverage, please call Medicare at 1-800-MEDICARE 1-800-633-4227 ; 24 hours a day 7 days a week. TTY TDD users should call 1-877-486-2048. Or, visit medicare.gov. Iron sucrose, 1 mg Venofer Imiglucerase, per unit Cerezyme Droperidol, up to 5 mg. Inapsine Propranolol HCL, up to 1mg Inderal Droperidol and fentanyl Innovar citrate, up to 2 ml ampule Insulin, per 5 units Humalog, Humulin, Iletin, Insulin Lispo, Novo Nordisk, NPH, Pork insulin, Regular insulin, Ultralente, Velosulin Insulin for administration Humalog, Humulin, Iletin, through DME per 50 units ; Insulin Lispo, Novo Nordisk, NPH, Pork insulin, Regular insulin, Ultralente, Velosulin Insulin Humalog, Regular, NPH, Lente, or Ultralente insulin Interferon beta-1a Avonex Interferon beta-1b Betaseron Itraconazole, 50 mg Sporonox IV Kanamycin sulfate, up to Kantrex, Klebcil 500 mg Kanamycin sulfate, up to 75 Kantrex mg Ketoroalc tromethamine, per Toradol 15 mg Cephalothin sodium, up to Cephalothin sodium, kKflin 1g Furosemide, up to 20 mg Lasix, Furomide M.D. Leuprolide acetate for Lupron Depot depot suspension ; , per 3.75 mg Levocarnitine, per 1g Carnitor Levofloxacin, 250 mg Levaquin Levorphanol tartrate, up to 2 Levo-Dromoran mg Hyoscyamine sulfate, up to Levsin 0.25 mg Chlordiazepoxide HCL Librium injection Lincomycin HCL, up to 300 Lincocin mg Linezolid, 200 mg Zyvox Lorazepam, 2 mg Ativan Mannitol, 25% in 50 ml Meperidine HCI, per 100 Demerol HCI mg Meperidine and Mepergan Promethazine HCI, up to 50 mg. Cattitude , : huggy: if you have a bendryl pill, give her a lil piece of it. A standard TUE application form completed by both the Player and his physician. The application must be supported by medical records reports and forwarded to the Players national Union. Form can be found at Schedule 3 of IRB Regulation 21.
|